The PRMT2IP knockout HT29 polyclonal cells constitute a CRISPR/Cas9-edited polyclonal knockout population targeting the PRMT2IP gene, designed for loss-of-function studies in a human colorectal adenocarcinoma epithelial model. This polyclonal format avoids clonal selection bias, providing a genetically heterogeneous background for functional genomics and pathway analysis of steroid hormone receptor signaling and transcriptional regulation.
The HT29 cell line, derived from a human colorectal adenocarcinoma, displays epithelial morphology and serves as a widely used intestinal epithelial and colorectal cancer model. These cells are amenable to differentiation studies and drug screening assays, offering a physiologically relevant system for investigating signaling pathways implicated in colorectal carcinogenesis. Their well-characterized biology and robust growth make them particularly suitable for gene disruption experiments aimed at dissecting hormone-responsive mechanisms.
PRMT2IP functions as a coactivator for steroid hormone receptors, such as estrogen receptor alpha (ESR1) and androgen receptor (AR), and is activated by ligands including estradiol and dihydrotestosterone. Upon ligand binding, PRMT2IP enhances transcriptional activation through interactions with protein arginine methyltransferase 2 (PRMT2) and other coactivators like NCOA1 (SRC1) and NCOA3, promoting expression of downstream targets CCND1 and MYC to regulate cell proliferation and differentiation. Additionally, PRMT2IP associates with splicing factors, linking hormone signaling to RNA processing. Thus, PRMT2IP integrates steroid hormone signals to modulate transcriptional programs involved in growth and differentiation.
In HT29 cells, knockout of PRMT2IP enables dissection of steroid receptor coactivation in the context of colorectal cancer, a disease where hormonal signaling can influence tumor progression. Loss of PRMT2IP may disrupt estrogen- and androgen-driven transcriptional networks, potentially altering proliferation and differentiation states. This knockout model therefore offers a valuable system to study the intersection between hormone-related disorders and intestinal epithelial biology, aiding the identification of molecular vulnerabilities in hormone-sensitive colorectal malignancies.
Researchers can employ this knockout population for diverse assays: western blotting and RT-qPCR to confirm gene disruption and assess downstream targets; co-immunoprecipitation to identify interaction partners; luciferase reporter assays to measure steroid receptor activity; ChIP-qPCR to evaluate chromatin occupancy; and proliferation assays to monitor tumorigenic behavior. These applications facilitate investigations into steroid receptor signaling, cancer progression, and gene regulation. For additional product information or technical support, please contact Ascent Research.
